Auteurs
Merge
Accueil
Racine
Merge
Exploration
Accueil
Racine
Accueil
Racine

Serveur d'exploration Tocilizumab - Merge (Accueil)

Index « Auteurs » - entrée « Marek Brzosko »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Marek Bohm < Marek Brzosko < Marek Frankowski  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
000A60 (2019) Marcin Milchert [Pologne] ; Joanna Makowska [Pologne] ; Olga Brzezi Ska [Pologne] ; Marek Brzosko [Pologne] ; Ewa Wi Sik-Szewczyk [Pologne]Monogenic autoinflammatory diseases in adults – a challenge to rheumatologic practice at the onset of the Polish national programme of interleukin 1 inhibitor treatment
002679 (2013) Roy M. Fleischmann [Afrique du Sud] ; Anne-Marie Halland ; Marek Brzosko ; Ruben Burgos-Vargas ; Christopher Mela ; Emma Vernon ; Joel M. KremerTocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
003404 (2013) Roy M. Fleischmann [États-Unis, Afrique du Sud, Pologne, Mexique, Royaume-Uni] ; Anne-Marie Halland ; Marek Brzosko ; Ruben Burgos-Vargas ; Christopher Mela ; Emma Vernon ; Joel M. KremerTocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results
003903 (2011) Joel M. Kremer [États-Unis] ; Ricardo Blanco ; Marek Brzosko ; Ruben Burgos-Vargas ; Anne-Marie Halland ; Emma Vernon ; Petra Ambs ; Roy FleischmannTocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
003C12 (2011) Joel M. Kremer [États-Unis] ; Ricardo Blanco [Espagne] ; Marek Brzosko [Pologne] ; Ruben Burgos-Vargas [Mexique] ; Anne-Marie Halland [Afrique du Sud] ; Emma Vernon [Royaume-Uni] ; Petra Ambs [Suisse] ; Roy Fleischmann [États-Unis]Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate: Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year
004535 (????) Joel M. Kremer [États-Unis] ; Ricardo Blanco [Espagne] ; Anne-Marie Halland [Afrique du Sud] ; Marek Brzosko [Pologne] ; Ruben Burgos-Vargas [Mexique] ; Christopher M. Mela [Royaume-Uni] ; Lucy Rowell [Royaume-Uni] ; Roy M. Fleischmann [États-Unis]Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Merge

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i -k "Marek Brzosko" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i  \
                -Sk "Marek Brzosko" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Merge
   |type=    indexItem
   |index=    Author.i
   |clé=    Marek Brzosko
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021